{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:25:55Z","timestamp":1773296755017,"version":"3.50.1"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1097\/mnm.0b013e32836141a0","type":"journal-article","created":{"date-parts":[[2013,4,12]],"date-time":"2013-04-12T09:45:44Z","timestamp":1365759944000},"page":"674-681","source":"Crossref","is-referenced-by-count":21,"title":["Intra-arterial injection of 131I-labeled Lipiodol for advanced hepatocellular carcinoma"],"prefix":"10.1097","volume":"34","author":[{"given":"Alina","family":"Lintia-Gaultier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Perret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Ansquer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Eug\u00e8ne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Kraeber-Bod\u00e9r\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Frampas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20210212","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics.","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"R2-9-20210212","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma.","volume":"362","author":"Llovet","year":"2003","journal-title":"Lancet"},{"key":"R7-9-20210212","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma.","volume":"56","year":"2012","journal-title":"J Hepatol"},{"key":"R8-9-20210212","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1600-0676.1990.tb00439.x","article-title":"Distribution of Lipiodol in hepatocellular carcinoma.","volume":"10","author":"Park","year":"1990","journal-title":"Liver"},{"key":"R11-9-20210212","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2967\/jnumed.107.044750","article-title":"Adjuvant intraarterial injection of 131I-labeled lipiodol after resection of hepatocellular carcinoma: progress report of a case-control study with a 5-year minimal follow-up.","volume":"49","author":"Boucher","year":"2008","journal-title":"J Nucl Med"},{"key":"R12-9-20210212","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update.","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"R13-9-20210212","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s002590100542","article-title":"Radiation exposure and radiation protection of the physician in iodine-131 Lipiodol therapy of liver tumours.","volume":"28","author":"Risse","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"R15-9-20210212","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2214\/AJR.04.1932","article-title":"Imaging features of hepatocellular carcinoma after transcatheter arterial chemoembolization and radiofrequency ablation.","volume":"187","author":"Lim","year":"2006","journal-title":"Am J Roentgenol"},{"key":"R18-9-20210212","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.addr.2008.04.013","article-title":"Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer.","volume":"60","author":"Hamoudeh","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"R21-9-20210212","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/SLA.0b013e3181571047","article-title":"Adjuvant intra-arterial iodine-131-labeled Lipiodol for resectable hepatocellular carcinoma. A prospective randomized trial-update on 5-year and 10-year survival.","volume":"247","author":"Lau","year":"2008","journal-title":"Ann Surg"},{"key":"R22-9-20210212","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejso.2006.10.039","article-title":"Prevention of intrahepatic recurrence by adjuvant (131)iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis.","volume":"33","author":"Tabone","year":"2007","journal-title":"Eur J Surg Oncol"},{"key":"R31-9-20210212","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.radonc.2006.11.001","article-title":"Intra-arterial injection of iodine-131-labeled Lipiodol for treatment of hepatocellular carcinoma.","volume":"82","author":"Boucher","year":"2007","journal-title":"Radiother Oncol"},{"key":"R35-9-20210212","first-page":"49","article-title":"Comparison of postembolization syndrome in the treatment of patients with unresectable hepatocellular carcinoma: trans-catheter chemo-embolization versus yttrium-90 glass microspheres.","volume":"3","author":"Goin","year":"2004","journal-title":"World J Nucl Med"},{"key":"R36-9-20210212","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/01.RVI.0000182185.47500.7A","article-title":"Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis.","volume":"16","author":"Georgiades","year":"2005","journal-title":"J Vasc Interv Radiol"},{"key":"R37-9-20210212","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/pds.2177","article-title":"Meta-analysis of interstitial pneumonia in studies evaluating iodine-131-labeled lipiodol for hepatocellular carcinoma using exact likelihood approach.","volume":"20","author":"Oger","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R39-9-20210212","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ctrv.2008.12.001","article-title":"Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy.","volume":"35","author":"Desar","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"R41-9-20210212","first-page":"348","article-title":"131-iodine Lipiodol therapy in hepatocellular carcinoma.","volume":"53","author":"Raoul","year":"2009","journal-title":"Q J Nucl Med Mol Imaging"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0b013e32836141a0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:19:10Z","timestamp":1620962350000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006231-201307000-00009"}},"subtitle":["a 7 years\u2019 experience"],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0b013e32836141a0","relation":{},"ISSN":["0143-3636"],"issn-type":[{"value":"0143-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}